Donna Neuberg

Senior Lecturer
This email address is being protected from spambots. You need JavaScript enabled to view it.



Donna Neuberg is involved in collaborative research in cancer in two different settings. She is the coordinating statistician for the Eastern Cooperative Oncology Group (ECOG), where she works with multi-center clinical trials in breast cancer. She also works with researchers in autologous and allogeneic bone marrow transplantation for hematologic malignancies at the Dana-Farber Cancer Institute, where issues of detection of minimal residual disease after curative therapy and the late complications of therapy are of particular interest.


Dr. Neuberg's methodological interests reflect her collaborative interests. She is currently involved in an examination of intermediate endpoints in controlled clinical trials, and, in particular, the reliability of time to progression or relapse as an indicator of improved survival. She is also exploring the recruitment of elderly patients to cancer clinical trials, using the ECOG database. Dr. Neuberg is also interested the efficient design of early phase clinical trials with multiple endpoints, and in the problems surrounding the analysis of data with missing observations over time.



Dr. Neuberg received her ScD in biostatistics from Harvard School of Public Health in 1988. She joined the Department of Biostatistical Science at DFCI in 1987. She has served as statistician for several solid tumor disease sites and for leukemia in the Eastern Cooperative Oncology Group. She works with the Lymphoma, Leukemia, and Pediatric Oncology Programs at DFCI.


Select Publications

Abaji R, Gagné V, Xu CJ, Spinella JF, Ceppi F, Laverdière C, Leclerc JM,
Sallan SE, Neuberg D, Kutok JL, Silverman LB, Sinnett D, Krajinovic M.
Whole-exome sequencing identified genetic risk factors for asparaginase-related
complications in childhood all patients. Oncotarget. 2017 May 17.


Perry AM, Brunner AM, Zou T, McGregor KL, Amrein PC, Hobbs GS, Ballen KK,
Neuberg DS, Fathi AT. Association between insurance status at diagnosis and
overall survival in chronic myeloid leukemia: A population-based study. Cancer.
2017 May 2.


Mantia C, Uhlmann EJ, Puligandla M, Weber GM, Neuberg D, Zwicker JI.
Predicting the higher rate of intracranial hemorrhage in glioma patients
receiving therapeutic enoxaparin. Blood. 2017 May 3. pii: blood-2017-02-767285.


Friedman AA, Xia Y, Trippa L, Le LP, Igras V, Frederick DT, Wargo JA, Tanabe
KK, Lawrence DP, Neuberg DS, Flaherty KT, Fisher D. Feasibility of
ultra-high-throughput functional screening of melanoma biopsies for discovery of novel cancer drug combinations. Clin Cancer Res. 2017 Apr 26. pii:


Weinberg OK, Gibson CJ, Blonquist TM, Neuberg D, Pozdnyakova O, Kuo F, Ebert
BL, Hasserjian RP. NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO classification. Am J Hematol. 2017 Mar 28.


Kalaitzidis D, Lee D, Efeyan A, Kfoury Y, Nayyar N, Sykes DB, Mercier FE,
Papazian A, Baryawno N, Victora GD, Neuberg D, Sabatini DM, Scadden DT. Amino acid-insensitive mTORC1 regulation enables nutritional stress resilience in
hematopoietic stem cells. J Clin Invest. 2017 Apr 3;127(4):1405-1413.


Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, Grauman PV, Hu ZH, Spellman SR, Lee SJ, Verneris MR, Hsu K, Fleischhauer K, Cutler C, Antin JH,
Neuberg D, Ebert BL. Prognostic Mutations in Myelodysplastic Syndrome after
Stem-Cell Transplantation. N Engl J Med. 2017 Feb 9;376(6):536-547.


Gibson CJ, Lindsley RC, Tchekmedyian V, Mar BG, Shi J, Jaiswal S, Bosworth A,
Francisco L, He J, Bansal A, Morgan EA, Lacasce AS, Freedman AS, Fisher DC,
Jacobsen E, Armand P, Alyea EP, Koreth J, Ho V, Soiffer RJ, Antin JH, Ritz J,
Nikiforow S, Forman SJ, Michor F, Neuberg D, Bhatia R, Bhatia S, Ebert BL. Clonal
Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell
Transplantation for Lymphoma. J Clin Oncol. 2017 May 10;35(14):1598-1605.


Stopa JD, Neuberg D, Puligandla M, Furie B, Flaumenhaft R, Zwicker JI. Protein
disulfide isomerase inhibition blocks thrombin generation in humans by
interfering with platelet factor V activation. JCI Insight. 2017 Jan


Fathi AT, Wander SA, Blonquist TM, Brunner AM, Amrein PC, Supko J, Hermance
NM, Manning AL, Sadrzadeh H, Ballen KK, Attar EC, Graubert TA, Hobbs G, Joseph C, Perry AM, Burke M, Silver R, Foster J, Bergeron M, Ramos AY, Som TT, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Chen YB. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. Haematologica. 2017 Apr;102(4):719-727.


Related Links